Literature DB >> 18413731

Analysis of the mechanisms mediating tumor-specific changes in gene expression in human liver tumors.

Luis G Acevedo1, Mark Bieda, Roland Green, Peggy J Farnham.   

Abstract

There is widespread interest in efficient characterization of differences between tumor and normal samples. Here, we show an effective methodology for genome-scale characterization of tumors. Using matched normal and tumor samples from liver cancer patients, as well as non-cancer-related normal liver tissue, we first determined changes in gene expression as monitored on RNA expression arrays. We identified several hundred mRNAs that were consistently changed in the tumor samples. To characterize the mechanisms responsible for creation of the tumor-specific transcriptome, we performed chromatin immunoprecipitation on microarray experiments to assay binding of RNA polymerase II, H3me3K27, and H3me3K9 and DNA methylation in 25,000 promoter regions. These experiments identified changes in active and silenced regions of the genome in the tumor cells. Finally, we used a "virtual comparative genomic hybridization" method to identify copy number alterations in the tumor samples. Through comparison of RNA polymerase II binding, chromatin structure, DNA methylation, and copy number changes, we suggest that the major contributor to creation of the liver tumor transcriptome was changes in gene copy number.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413731      PMCID: PMC2567918          DOI: 10.1158/0008-5472.CAN-07-5590

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Expression of human SOX18 in normal tissues and tumors.

Authors:  Tetsuroh Saitoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2002-09       Impact factor: 4.101

2.  Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma.

Authors:  Honghai Li; Xiaoyong Fu; Yao Chen; Yi Hong; Yexiong Tan; Huifang Cao; Mengchao Wu; Hongyang Wang
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

3.  Comparison of sample preparation methods for ChIP-chip assays.

Authors:  Henriette O'Geen; Charles M Nicolet; Kim Blahnik; Roland Green; Peggy J Farnham
Journal:  Biotechniques       Date:  2006-11       Impact factor: 1.993

4.  Suz12 binds to silenced regions of the genome in a cell-type-specific manner.

Authors:  Sharon L Squazzo; Henriette O'Geen; Vitalina M Komashko; Sheryl R Krig; Victor X Jin; Sung-wook Jang; Raphael Margueron; Danny Reinberg; Roland Green; Peggy J Farnham
Journal:  Genome Res       Date:  2006-06-02       Impact factor: 9.043

5.  Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.

Authors:  Kouichi Kimura; Ai Wakamatsu; Yutaka Suzuki; Toshio Ota; Tetsuo Nishikawa; Riu Yamashita; Jun-ichi Yamamoto; Mitsuo Sekine; Katsuki Tsuritani; Hiroyuki Wakaguri; Shizuko Ishii; Tomoyasu Sugiyama; Kaoru Saito; Yuko Isono; Ryotaro Irie; Norihiro Kushida; Takahiro Yoneyama; Rie Otsuka; Katsuhiro Kanda; Takahide Yokoi; Hiroshi Kondo; Masako Wagatsuma; Katsuji Murakawa; Shinichi Ishida; Tadashi Ishibashi; Asako Takahashi-Fujii; Tomoo Tanase; Keiichi Nagai; Hisashi Kikuchi; Kenta Nakai; Takao Isogai; Sumio Sugano
Journal:  Genome Res       Date:  2005-12-12       Impact factor: 9.043

6.  Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma.

Authors:  N Kondoh; M Shuda; K Tanaka; T Wakatsuki; A Hada; M Yamamoto
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

7.  Assessment of chromosomal losses and gains in hepatocellular carcinoma.

Authors:  Joon Chang; Nam-Gyun Kim; Zhe Piao; Chanil Park; Kang-Sik Park; Young-Ki Paik; Woo-Jung Lee; Byong Ro Kim; Hoguen Kim
Journal:  Cancer Lett       Date:  2002-08-28       Impact factor: 8.679

8.  The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.

Authors:  Hiroaki Higashitsuji; Hisako Higashitsuji; Katsuhiko Itoh; Toshiharu Sakurai; Toshikazu Nagao; Yasuhiko Sumitomo; Haruhiko Sumitomo; Tomoko Masuda; Simon Dawson; Yutaka Shimada; R John Mayer; Jun Fujita
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

9.  TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Authors:  Kohichiroh Yasui; Shigeki Arii; Chen Zhao; Issei Imoto; Masakazu Ueda; Hisaki Nagai; Mitsuru Emi; Johji Inazawa
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

10.  OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci.

Authors:  Wen-Hui Su; Chuan-Chuan Chao; Shiou-Hwei Yeh; Ding-Shinn Chen; Pei-Jer Chen; Yuh-Shan Jou
Journal:  Nucleic Acids Res       Date:  2006-11-10       Impact factor: 16.971

View more
  23 in total

1.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

2.  E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites.

Authors:  Alina Rabinovich; Victor X Jin; Roman Rabinovich; Xiaoqin Xu; Peggy J Farnham
Journal:  Genome Res       Date:  2008-10-03       Impact factor: 9.043

Review 3.  Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.

Authors:  Carmen Berasain; Saioa Goñi; Josefa Castillo; María Ujue Latasa; Jesús Prieto; Matías A Avila
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

4.  Integrative genomics: liver regeneration and hepatocellular carcinoma.

Authors:  Zeynep Coban; Michelle Craig Barton
Journal:  J Cell Biochem       Date:  2012-07       Impact factor: 4.429

5.  Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Kendell Clement; Michael J Ziller; Patrick Boyle; Jean Fan; Hongcang Gu; Kristen Stevenson; Carrie Sougnez; Lili Wang; Shuqiang Li; Dylan Kotliar; Wandi Zhang; Mahmoud Ghandi; Levi Garraway; Stacey M Fernandes; Kenneth J Livak; Stacey Gabriel; Andreas Gnirke; Eric S Lander; Jennifer R Brown; Donna Neuberg; Peter V Kharchenko; Nir Hacohen; Gad Getz; Alexander Meissner; Catherine J Wu
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

6.  Identifying master regulators of cancer and their downstream targets by integrating genomic and epigenomic features.

Authors:  Olivier Gevaert; Sylvia Plevritis
Journal:  Pac Symp Biocomput       Date:  2013

7.  Using ChIP-chip technology to reveal common principles of transcriptional repression in normal and cancer cells.

Authors:  Vitalina M Komashko; Luis G Acevedo; Sharon L Squazzo; Sushma S Iyengar; Alina Rabinovich; Henriette O'Geen; Roland Green; Peggy J Farnham
Journal:  Genome Res       Date:  2008-03-17       Impact factor: 9.043

8.  Histone H3 lysine 27 methylation asymmetry on developmentally-regulated promoters distinguish the first two lineages in mouse preimplantation embryos.

Authors:  John Arne Dahl; Andrew H Reiner; Arne Klungland; Teruhiko Wakayama; Philippe Collas
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

9.  DNMT1 is a required genomic regulator for murine liver histogenesis and regeneration.

Authors:  Kosuke Kaji; Valentina M Factor; Jesper B Andersen; Marian E Durkin; Akira Tomokuni; Jens U Marquardt; Matthias S Matter; Tanya Hoang; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2016-04-28       Impact factor: 17.425

10.  Fast genomic muChIP-chip from 1,000 cells.

Authors:  John Arne Dahl; Andrew H Reiner; Philippe Collas
Journal:  Genome Biol       Date:  2009-02-10       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.